Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (38)
Valeriy V. Breder, Evgenii V. Ledin, Viacheslav A. Chubenko, Rashida V. Orlova, Vladislav V. Petkau & Ilya A. Pokataev. (2023) Place of durvalumab in the treatment of biliary tract cancer: A review. Journal of Modern Oncology 24:4, pages 407-412.
Crossref
Crossref
Oula El Atat, Rayan Naser, Maya Abdelkhalek, Ralph Habib & Mirvat El Sibai. (2022) Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). Oncology Letters 25:2.
Crossref
Crossref
Dhananjay Yadav, Minseok Kwak, Pallavi Singh Chauhan, Nidhi Puranik, Peter C.W. Lee & Jun-O Jin. (2022) Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Seminars in Cancer Biology 86, pages 909-922.
Crossref
Crossref
Rayan Naser, Hrag Dilabazian, Hadi Bahr, Aya Barakat & Mirvat El‑Sibai. (2022) A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy (Review). Oncology Reports 48:5.
Crossref
Crossref
Sarmini Munisamy, Ammu Kutty Radhakrishnan, Premdass Ramdas, Priscilla Josephine Samuel & Vivek Ajit Singh. (2022) Immune Biomarkers in Blood from Sarcoma Patients: A Pilot Study. Current Oncology 29:8, pages 5585-5603.
Crossref
Crossref
Sara Franzi, Giovanni Mattioni, Erika Rijavec, Giorgio Alberto Croci & Davide Tosi. (2022) Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature. Journal of Clinical Medicine 11:9, pages 2629.
Crossref
Crossref
Yao Jin, Jiayan Wei, Yiming Weng, Jia Feng, Zexi Xu, Peiwei Wang, Xue Cui, Xinyi Chen, Jinsong Wang & Min Peng. (2022) Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology 12.
Crossref
Crossref
Hugo Teixeira Farinha, Antonia Digklia, Dimitrios Schizas, Nicolas Demartines, Markus Schäfer & Styliani Mantziari. (2022) Immunotherapy for Esophageal Cancer: State-of-the Art in 2021. Cancers 14:3, pages 554.
Crossref
Crossref
Emma L. Newport, Ana Rita Pedrosa, Alexandra Njegic, Kairbaan M. Hodivala-Dilke & José M. Muñoz-Félix. (2021) Improved Immunotherapy Efficacy by Vascular Modulation. Cancers 13:20, pages 5207.
Crossref
Crossref
Anica Högner & Peter Thuss-Patience. (2021) Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma. Pharmaceuticals 14:2, pages 151.
Crossref
Crossref
Fadi Haddad & Naval Daver. 2021. Immunotherapy. Immunotherapy
273
295
.
Rachel Jug, Coral X. Giovacchini, Beiyu Liu, Cynthia L. Green, Jeffrey M. Clarke, Kamran Mahmood & Elizabeth N. Pavlisko. (2020) EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non–small cell lung cancer. Journal of the American Society of Cytopathology 9:6, pages 485-493.
Crossref
Crossref
Yingying Fan, Hamada A.A. Noreldeen, Lei You, Xinyu Liu, Xue Pan, Zhichao Hou, Qiangming Li, Xiangnan Li & Guowang Xu. (2020) Lipid alterations and subtyping maker discovery of lung cancer based on nontargeted tissue lipidomics using liquid chromatography–mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 190, pages 113520.
Crossref
Crossref
Qi Fu & Zhenhai Yu. (2020) Phosphoglycerate kinase 1 (PGK1) in cancer: A promising target for diagnosis and therapy. Life Sciences 256, pages 117863.
Crossref
Crossref
Lijuan Wang, Xizhi Luo, Chao Cheng, Christopher I. Amos, Guoshuai Cai & Feifei Xiao. (2020) A gene expression-based immune signature for lung adenocarcinoma prognosis. Cancer Immunology, Immunotherapy 69:9, pages 1881-1890.
Crossref
Crossref
Paolo D’Arrigo, Martina Tufano, Anna Rea, Vincenza Vigorito, Nunzia Novizio, Salvatore Russo, Maria Fiammetta Romano & Simona Romano. (2020) Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Current Medicinal Chemistry 27:15, pages 2402-2448.
Crossref
Crossref
Hong‐Min Wang, Xiao‐Hong Zhang, Li‐Qun Ye, Kai Zhang, Ning‐Ning Yang, Shen Geng, Jing Chen, Shun‐Xin Zhao, Kang‐Li Yang & Fei‐Fei Fan. (2020)
Insufficient CD100 shedding contributes to suppression of CD8
+
T‐cell activity in non‐small cell lung cancer
. Immunology 160:2, pages 209-219.
Crossref
Crossref
Shreya Thakkar, Dilip Sharma, Kiran Kalia & Rakesh K. Tekade. (2020) Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review. Acta Biomaterialia 101, pages 43-68.
Crossref
Crossref
Mei-Ren Pan, Cheng-Che Wu, Jung-Yu Kan, Qiao-Lin Li, Shu-Jyuan Chang, Chun-Chieh Wu, Chung-Liang Li, Fu Ou-Yang, Ming-Feng Hou, Hon-Kan Yip & Chi-Wen Luo. (2019) Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers 12:1, pages 94.
Crossref
Crossref
Javeria Zaheer, Hyeongi Kim, Yong-Jin Lee, Jin Su Kim & Sang Moo Lim. (2019) Combination Radioimmunotherapy Strategies for Solid Tumors. International Journal of Molecular Sciences 20:22, pages 5579.
Crossref
Crossref
Elissar Moujaess, Fady Gh Haddad, Roland Eid & Hampig Raphael Kourie. (2019) The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. Immunotherapy 11:16, pages 1409-1422.
Crossref
Crossref
Cinzia Dello Russo, Dimitri Gagliardi, Ronnie Ramlogan & Pierluigi Navarra. (2019) Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer. Clinical Therapeutics 41:5, pages 982-991.
Crossref
Crossref
Yun Xia, Xian-Yi Cai, Ji-Quan Fan, Li-Ling Zhang, Jing-Hua Ren, Zhen-Yu Li, Rui-Guang Zhang, Fang Zhu & Gang Wu. (2019) The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms. International Journal of Cancer 144:9, pages 2227-2238.
Crossref
Crossref
Deng Pan, Jiaxi Chen, Chunchao Feng, Weibo Wu, Yanjin Wang, Jiao Tong & Dapeng Zhou. (2019) Preferential Localization of MUC1 Glycoprotein in Exosomes Secreted by Non-Small Cell Lung Carcinoma Cells. International Journal of Molecular Sciences 20:2, pages 323.
Crossref
Crossref
Naghmehossadat Eshghi, Linda L. Garland, Emily Nia, Robert Betancourt, Elizabeth Krupinski & Phillip H. Kuo. (2018)
18
F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer
. Journal of Nuclear Medicine Technology 46:3, pages 260-264.
Crossref
Crossref
Mohamad Mazen Gafeer, Kareem Hosny Mohammed, Claudia Ormenisan-Gherasim, Fahad Choudhary, Momin T. Siddiqui & Cynthia Cohen. (2018) Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA In Situ Hybridization. Applied Immunohistochemistry & Molecular Morphology 26:8, pages e86-e90.
Crossref
Crossref
Izuchukwu Ibe, Adam Sahlstrom, Minh N. Nguyen, Dieter Lindskog, Gary E. Friedlaender & Francis Y. Lee. (2018) Immuno-oncologic Approach to Musculoskeletal Tumors. Techniques in Orthopaedics 33:3, pages 140-147.
Crossref
Crossref
Mirella Marino, Paolo Visca & Margaret Ottaviano. (2018) PD-L1 Testing in Lung Cancer: An International Pathologist’s Initiative in an Unknown “Middle Earth”. Journal of Thoracic Oncology 13:9, pages 1239-1241.
Crossref
Crossref
Andrea Bianco, Umberto Malapelle, Danilo Rocco, Fabio Perrotta & Gennaro Mazzarella. (2018) Targeting immune checkpoints in non small cell lung cancer. Current Opinion in Pharmacology 40, pages 46-50.
Crossref
Crossref
Dan Chen, Huanhuan Sha, Tianmu Hu, Shuchen Dong, Junying Zhang, Siwen Liu, Haixia Cao, Rong Ma, Yang Wu, Changwen Jing, Zhuo Wang, Jianzhong Wu & Jifeng Feng. (2018) Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer. Cell Death & Disease 9:3.
Crossref
Crossref
Zihua Pan, Li Liu, Wenjing Nie, Sinead Miggin, Fuman Qiu, Yi Cao, Jinbin chen, Binyao Yang, Yifeng Zhou, Jiachun Lu & Lei Yang. (2018) Long non-coding RNA AGER-1 functionally upregulates the innate immunity gene AGER and approximates its anti-tumor effect in lung cancer. Molecular Carcinogenesis 57:3, pages 305-318.
Crossref
Crossref
Ping-Pin Zheng, Jin Li & Johan M Kros. (2018) Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Medicinal Research Reviews 38:1, pages 325-376.
Crossref
Crossref
Xia Wang, Zhiqiang Zhang, Huimin Cao, Wenyi Niu, Mingying Li, Xiu'e Xi & Jing Wang. (2017) Human papillomavirus type 16 E6 oncoprotein promotes proliferation and invasion of non-small cell lung cancer cells through Toll-like receptor 3 signaling pathway. Journal of Medical Virology 89:10, pages 1852-1860.
Crossref
Crossref
Tzu-Rong Peng, Fang-Pei Tsai & Ta-Wei Wu. (2017) Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. International Immunopharmacology 49, pages 85-94.
Crossref
Crossref
ChengHan Mei, ShunChang Zhou, Lin Zhu, JiaXiong Ming, FanDian Zeng & Rong Xu. (2017) Antitumor Effects of Laminaria Extract Fucoxanthin on Lung Cancer. Marine Drugs 15:2, pages 39.
Crossref
Crossref
Guangbo Liu, Fen Pei, Fengqing Yang, Lingxiao Li, Amit Amin, Songnian Liu, J. Buchan & William Cho. (2017) Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences 18:2, pages 367.
Crossref
Crossref
Ju Hwan Cho. (2017) Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles. Immune Network 17:6, pages 378.
Crossref
Crossref
Allan Ramos-Esquivel, Alicia van der Laat, Raquel Rojas-Vigott, Melissa Juárez & Luis Corrales-Rodríguez. (2017) Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open 2:3, pages e000236.
Crossref
Crossref